Melius Microbiomics

1 known investors

Melius MicroBiomics develops genetically engineered microbial therapeutics (GEMM™) to treat gut inflammation and dysbiosis in humans and animals. The company uses proprietary genetic platforms (BioPersist™ and BioColonize™) to create modified bacteria that survive in inflamed intestines and demonstrate superior efficacy compared to existing therapies.